Humana Beats 3Q Estimates, Raises FY2026 Adjusted EPS Guidance to at Least $9.50
HUM has more than doubled off its 52-week low of $163.11.
Summary
Humana beat its own third-quarter guidance, posting a 93.7% Insurance benefit ratio and a $0.70 adjusted loss per share versus roughly $1.00 expected, and raised FY2026 adjusted EPS guidance to at least $9.50 from at least $9.00. The GAAP guidance jump to at least $15.09 is mostly non-cash put/call and option-liability accounting, not operating earnings.
Updates
· dpa-AFX — Humana's FY2026 GAAP EPS guidance is at least $15.09, up from at least $6.52, alongside adjusted EPS of at least $9.50; HUM traded at $409.00 premarket, down 0.70%.
Key Events · Earnings and Guidance · HUM
-
3Q26 Beats and Guidance Raised
Adjusted loss per share of $0.70 versus guidance of approximately $1.00, on revenues of $41,155 million. FY2026 adjusted EPS guidance raised to at least $9.50 from at least $9.00.
-
Benefit Ratio Beats Plan
Insurance segment GAAP benefit ratio of 93.7% came in favorable to management's guidance of 'slightly above 94 percent'; medical and pharmacy cost trends are in line to better than the 'high single digit' expectation.
-
GAAP Guidance Jump Is Non-Cash
GAAP EPS guidance revised to at least $15.09 from at least $6.52, driven largely by a non-cash reversal of the approximately $1.2 billion net put liability from the former WCAS joint ventures and a new $2.14 per share option liability from the BlackRock JV expected in 4Q26.
-
Fourth Quarter Benefit Ratio Guided Above 95.5%
Management expects the 4Q26 Insurance segment benefit ratio just above 95.5%, with the consolidated ratio slightly higher; a virtual investor update is set for December 10, 2026.
Analysis · HUM · Finance
The third quarter came in ahead of Humana's own plan, and that is what drove the guidance raise. The Insurance segment benefit ratio of 93.7% beat guidance of 'slightly above 94 percent', while the adjusted loss of $0.70 per share was far better than the roughly $1.00 loss management had guided to. On that basis, full-year adjusted EPS guidance moves up to at least $9.50 from at least $9.00, even with the Bonus Year 2026 Star Ratings headwind still in the numbers. GAAP guidance jumps to at least $15.09 from at least $6.52, but most of that swing is non-cash: a $1.2 billion reversal of the net put liability tied to the old WCAS primary care joint ventures, plus a new $2.14 per share option liability from the BlackRock JV that will hit GAAP results in the fourth quarter. The real operating story is medical cost trend running in line to better than the 'high single digit' expectation, with the operating cost ratio down 80 basis points year to date. Near term, the fourth quarter is the test: management guides the Insurance benefit ratio just above 95.5%, and the December 10 investor update is where the 2028 margin framework gets marked to market.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HUM was trading at $413.59 on NYSE in the Finance sector, with a market capitalization of approximately $49.4B. The 52-week trading range was $163.11 to $456.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.